ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.

[1]  M. Socinski,et al.  IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[2]  Myeong-Jin Kim,et al.  Incorporation of Ancillary MRI Features into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment for Hepatocellular Carcinoma. , 2021, AJR. American journal of roentgenology.

[3]  N. Girard,et al.  Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Scagliotti,et al.  Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations , 2021, Cancers.

[5]  A. Tafreshi,et al.  Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Jänne,et al.  Overcoming therapy resistance in EGFR-mutant lung cancer , 2021, Nature Cancer.

[7]  Joe Y. Chang,et al.  NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  M. Tsuboi,et al.  Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. , 2021, Journal of Thoracic Oncology.

[9]  M. Tsuboi,et al.  P03.02 Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA , 2021 .

[10]  A. Drilon,et al.  FP14.07 Combination Osimertinib plus Selpercatinib for EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) with Acquired RET fusions , 2021 .

[11]  Summer S. Han,et al.  Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Yi-long Wu,et al.  Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Yukiko Nakamura,et al.  Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations , 2020, JTO clinical and research reports.

[14]  G. Scagliotti,et al.  International Association for the Study of Lung Cancer (IASLC) , 2019, Annals of Oncology.

[15]  Sri Harsha Tekumalla,et al.  Cardiac Safety of Osimertinib: A Review of Data , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Lim,et al.  Beyond osimertinib: The development of 3rd-generation EGFR Tyrosine Kinase Inhibitors. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  M. Ahn,et al.  Recent Advances on the Role of EGFR TKIs in the Management of NSCLC with Uncommon, non-exon 20 insertion EGFR Mutations. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  T. Yamanaka,et al.  Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. , 2020, Lung cancer.

[19]  H. Blons,et al.  PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. , 2020, Lung cancer.

[20]  M. Tsuboi,et al.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[21]  A. Cardona,et al.  EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. , 2020, Cancer Treatment Reviews.

[22]  A. Gemma,et al.  Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with epidermal growth factor receptor T790M-positive non-small cell lung cancer treated with osimertinib in Japan. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  A. Addeo,et al.  Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer , 2020, Cancer Genomics & Proteomics.

[24]  N. Leighl,et al.  Mechanisms of osimertinib resistance and emerging treatment options. , 2020, Lung cancer.

[25]  N. Normanno,et al.  cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation? , 2020, EBioMedicine.

[26]  L. Sequist,et al.  Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Y. Yarden,et al.  The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy , 2020, Molecular Cancer.

[28]  Ying Cheng,et al.  Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis , 2020 .

[29]  A. Russo,et al.  The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. , 2020, Cancer treatment reviews.

[30]  Xiaoqing Yu,et al.  PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy. , 2020, Lung cancer.

[31]  D. Planchard,et al.  Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. , 2020, Critical reviews in oncology/hematology.

[32]  S. Peters,et al.  Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice? , 2020, The Lancet. Oncology.

[33]  L. Sequist,et al.  Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. , 2020, The Lancet. Oncology.

[34]  M. Ahn,et al.  TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  M. Tiemann,et al.  TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC , 2020, Oncotarget.

[36]  Lei Dong,et al.  Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis , 2020, World journal of surgical oncology.

[37]  Edward S. Kim,et al.  Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Database of 693 Cases. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  D. Pe’er,et al.  Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer , 2020, Clinical Cancer Research.

[39]  A. Gemma,et al.  Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Dutt,et al.  Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Ahn,et al.  Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Ahn,et al.  Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Shih,et al.  Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[44]  J. Ahn,et al.  Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. , 2019, The Lancet. Oncology.

[45]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[46]  A. Nicholson,et al.  The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[47]  C. Paweletz,et al.  Brief Report: EGFR-mutated lung cancers resistant to osimertinib through EGFR-C797S respond to 1st generation reversible EGFR inhibitors but eventually acquire EGFR-T790M/C797S in preclinical models and clinical samples. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[48]  N. Girard,et al.  Nivolumab + chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722) , 2019, Annals of Oncology.

[49]  D. Pe’er,et al.  Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[50]  E. Giovannetti,et al.  Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer , 2019, British Journal of Cancer.

[51]  F. Cappuzzo,et al.  Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib , 2019, Cancers.

[52]  Mong-Wei Lin,et al.  Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy. , 2019, Lung cancer.

[53]  Ying Cheng,et al.  Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer , 2019, Clinical Cancer Research.

[54]  J. Heymach,et al.  Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy , 2019, Nature Reviews Cancer.

[55]  A. Drilon,et al.  Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  Yi-long Wu,et al.  ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. , 2019, Future oncology.

[57]  Ying Cheng,et al.  Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Jih-Hsiang Lee,et al.  Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. , 2019, The oncologist.

[59]  N. Schultz,et al.  EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[61]  M. Kris,et al.  Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. , 2019 .

[62]  A. Gemma,et al.  Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. , 2019, The Lancet. Oncology.

[63]  M. Socinski,et al.  Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. , 2019, The Lancet. Respiratory medicine.

[64]  Sung Sook Lee,et al.  Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[65]  M. Ladanyi,et al.  High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden , 2019, Clinical Cancer Research.

[66]  H. Satoh,et al.  Rapid effect of osimertinib re-challenge on brain metastases developing during salvage cytotoxic chemotherapy after osimertinib treatment failure: A case report. , 2019, Molecular and clinical oncology.

[67]  Li Zhang,et al.  Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer , 2019, EBioMedicine.

[68]  Paul H. Huang,et al.  Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer , 2019, Signal Transduction and Targeted Therapy.

[69]  M. Mino‐Kenudson,et al.  EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  M. Kris,et al.  SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  A. Kohlmann,et al.  Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[72]  H. Nishimura,et al.  Pattern of recurrence after CyberKnife stereotactic body radiotherapy for peripheral early non-small cell lung cancer. , 2019, Journal of thoracic disease.

[73]  D. Planchard,et al.  Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy , 2018, JAMA oncology.

[74]  C. Paweletz,et al.  Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib , 2018, JAMA oncology.

[75]  E. Schuuring,et al.  P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer , 2018, Journal of Thoracic Oncology.

[76]  Gregory Riely,et al.  P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789 , 2018, Journal of Thoracic Oncology.

[77]  J. Barrett,et al.  Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  J. McPherson,et al.  Diverse EGFR Exon 20 Insertions and Co‐Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[79]  S. Digumarthy,et al.  Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. , 2018, Cancer discovery.

[80]  M. Ladanyi,et al.  Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. , 2018, JCO precision oncology.

[81]  Paul Baas,et al.  Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[82]  E. Cho,et al.  CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  Tetsuya Tanimoto,et al.  EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[84]  Zhiguang Li,et al.  YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity. , 2018, Cancer discovery.

[85]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[86]  Y. Oda,et al.  PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. , 2018, Lung cancer.

[87]  B. Goh,et al.  Third generation EGFR TKIs: current data and future directions , 2018, Molecular Cancer.

[88]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[89]  V. Gebski,et al.  Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis , 2017, JAMA oncology.

[90]  J. Horton,et al.  A Phase II Study of Pembrolizumab in EGFR‐Mutant, PD‐L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[91]  Thomas John,et al.  Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  N. Rosenfeld,et al.  Are liquid biopsies a surrogate for tissue EGFR testing? , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[93]  M. Kris,et al.  Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases , 2018, Cancer.

[94]  T. Morimoto,et al.  Early Immune‐Related Adverse Events and Association with Outcome in Advanced Non‐Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[95]  Yi-long Wu,et al.  A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. , 2017, Lung cancer.

[96]  Ying Cheng,et al.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[97]  Yi-long Wu,et al.  Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First‐ and Third‐Generation EGFR TKIs and Shifts Allelic Configuration at Resistance , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[98]  H. Do,et al.  Combination Osimertinib and Gefitinib in C797S and T790M EGFR‐Mutated Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[99]  J. Ahn,et al.  Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. , 2017, The Lancet. Respiratory medicine.

[100]  Maximilian Diehn,et al.  Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers , 2017, Nature Genetics.

[101]  Jie Yang,et al.  Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  W. Curran,et al.  Next‐generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy , 2017, Cancer.

[103]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[104]  M. Tsao,et al.  Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). , 2017, Lung cancer.

[105]  Minghui Zhang,et al.  PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis , 2017, Scientific Reports.

[106]  Yi-long Wu,et al.  EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer , 2017, Oncoimmunology.

[107]  M. Oudkerk,et al.  Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  P. Park,et al.  Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  S. Kobayashi,et al.  Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3–PD‐L1 ≥50% Expression in Lung Adenocarcinoma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[110]  W. Jochum,et al.  Clinical Outcome of ALK‐Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co‐Mutations Receiving Tyrosine Kinase Inhibitors (TKIs) , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[111]  Xianhe Xie,et al.  The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC , 2017, Oncotarget.

[112]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[113]  V. Gebski,et al.  Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[114]  N. Normanno,et al.  Targeting the EGFR T790M mutation in non-small-cell lung cancer , 2017, Expert opinion on therapeutic targets.

[115]  S. Gettinger,et al.  Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  K. O'Byrne,et al.  Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[117]  M. Ahn,et al.  AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases , 2016, Science Translational Medicine.

[118]  C. Paweletz,et al.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  F. Cappuzzo,et al.  Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. , 2016, Lung cancer.

[120]  T. Mitsudomi,et al.  Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy , 2016, Cancer science.

[121]  S. Digumarthy,et al.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.

[122]  M. Ahn,et al.  Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases , 2016, Journal of pathology and translational medicine.

[123]  Jean Mosser,et al.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.

[124]  Jingting Jiang,et al.  PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations , 2016, Cancer biology & therapy.

[125]  A. Jemal,et al.  Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non–Small Cell Lung Cancer in the U.S. National Cancer Data Base , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[126]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[127]  Jih-Hsiang Lee,et al.  Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[128]  Y. Yatabe,et al.  EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[129]  Chun-Ming Tsai,et al.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  L. Sequist,et al.  Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. , 2015, The Lancet. Oncology.

[131]  R. Franco,et al.  EGFR mutations in lung cancer: from tissue testing to liquid biopsy. , 2015, Future oncology.

[132]  P. Jänne,et al.  EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors , 2015, Clinical Cancer Research.

[133]  Cheng-Ta Yang,et al.  Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[134]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[135]  S. Fujita,et al.  High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs , 2015, Cancer Chemotherapy and Pharmacology.

[136]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[137]  Diane D. Liu,et al.  Adding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer , 2015, International journal of radiation oncology, biology, physics.

[138]  D. Kim,et al.  Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[139]  A. Chella,et al.  PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients , 2014, British Journal of Cancer.

[140]  T. Kohno,et al.  Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer. , 2015, International journal of radiation oncology, biology, physics.

[141]  Y. Nakanishi,et al.  Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[142]  Sang‐wook Lee,et al.  Postoperative radiation therapy following the incomplete resection of a non-small cell lung cancer , 2014, Radiation oncology journal.

[143]  Masahiro Endo,et al.  The Impact of Clinical Outcomes According to EGFR Mutation Status in Patients with Locally Advanced Lung Adenocarcinoma Who Recieved Concurrent Chemoradiotherapy , 2014, American journal of clinical oncology.

[144]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[145]  T. Mok,et al.  Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation , 2014, Clinical Cancer Research.

[146]  Travis J Cohoon,et al.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. , 2013, Cancer discovery.

[147]  J. Jett,et al.  Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  I. Wistuba,et al.  Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. , 2013, Lung cancer.

[150]  J. Donington,et al.  Surgical Management of Lung Cancer , 2013, Seminars in Interventional Radiology.

[151]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[152]  Suzanne E Dahlberg,et al.  Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[153]  Marc Ladanyi,et al.  EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics , 2013, Molecular Cancer Therapeutics.

[154]  Suresh Senan,et al.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. , 2012, The Lancet. Oncology.

[155]  J. Shih,et al.  Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. , 2012, The Lancet. Oncology.

[156]  Sung-Liang Yu,et al.  Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  M. Kris,et al.  Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[158]  S. Kobayashi,et al.  EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. , 2012, The Lancet. Oncology.

[159]  Jean-Luc Coll,et al.  The multiple roles of amphiregulin in human cancer. , 2011, Biochimica et biophysica acta.

[160]  M. Ladanyi,et al.  Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib , 2011, Clinical Cancer Research.

[161]  P Baas,et al.  Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[162]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[163]  P. Jänne,et al.  Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[164]  Richard J Stephens,et al.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[165]  J. Crowley,et al.  Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[166]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.